Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’

Schöffski, P, Wozniak, A, Kasper, B et al. (23 more authors) (2018) Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Annals of Oncology, 29 (3). pp. 758-765. ISSN 0923-7534

Abstract

Metadata

Authors/Creators:
  • Schöffski, P
  • Wozniak, A
  • Kasper, B
  • Aamdal, S
  • Leahy, MG
  • Rutkowski, P
  • Bauer, S
  • Gelderblom, H
  • Italiano, A
  • Lindner, LH
  • Hennig, I
  • Strauss, S
  • Zakotnik, B
  • Anthoney, A
  • Albiges, L
  • Blay, J-Y
  • Reichardt, P
  • Sufliarsky, J
  • van der Graaf, WTA
  • Debiec-Rychter, M
  • Sciot, R
  • Van Cann, T
  • Marréaud, S
  • Raveloarivahy, T
  • Collette, S
  • Stacchiotti, S
Keywords: alveolar soft part sarcoma, ASPS, transcription factor E3 (TFE3) gene rearrangement, MET expression, MET tyrosine kinase inhibitor, crizotinib
Dates:
  • Published: 1 March 2018
  • Published (online): 5 December 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 31 Oct 2019 10:58
Last Modified: 31 Oct 2019 10:58
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdx774
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics